TP53 and acute myeloid leukemia: Biomarkers of the responses to individual treatments and statistical significances are listed in Figure 6I. Two primary AMLs carried TP53 gene mutations, one in a FLT3 wild-type AML (A1) and the other in a FLT3-TKD AML (A2).